Hoppa till innehåll
  • Home
  • About us
    • Team
    • Board of Directors 
  • Our product
    • EMP16
    • Clinical Program
  • Publications
  • News & Media
    • Media
    • Press Releases
    • Blog
  • Contact
  • Home
  • About us
    • Team
    • Board of Directors 
  • Our product
    • EMP16
    • Clinical Program
  • Publications
  • News & Media
    • Media
    • Press Releases
    • Blog
  • Contact

news

  • Home
  • News & Media
Press releases
Empros Pharma Launches Pilot Trial Ahead of EMP16 Phase III Program
Press releases
Empros phase 2b obesity trial enrollment complete in only one month..
Blog
A short overview of the chronic disease obesity
Press releases
Empros pharma doses first patients in large scale clinical study of anti-obesity drug EMP-16
Press releases
Empros secures 80 msek funding to support development of obesity treatment candidate – EMP 16

Empros Pharma was founded in 2013 by researchers and entrepreneurs at Uppsala University together with the investor Flerie Invest. The company is developing EMP16, a pharmaceutical weight management treatment, planned to be ready for launch in 2027. 

Pages

  • Home
  • About us
    • Team
    • Board of Directors 
  • Our product
    • EMP16
    • Clinical Program
  • News & Media
    • Media
    • Press Releases
    • Blog
  • Contact
  • Home
  • About us
    • Team
    • Board of Directors 
  • Our product
    • EMP16
    • Clinical Program
  • News & Media
    • Media
    • Press Releases
    • Blog
  • Contact

Contact

  • info@emprospharma.com
  • Nanna Svartz väg 4, 171 65, Solna
Linkedin
© 2025 empros pharma

Hemsidan är byggd av Weblab